- *Corresponding Author:
- B. Chauhan
B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej-Gandhinagar Highway, Thaltej, Ahmedabad-380 054, India
E-mail: [email protected]
|Date of Submission||20 April 2005|
|Date of Revision||12 September 2005|
|Date of Acceptance||01 August 2006|
|Indian J Pharm Sci, 2006, 68 (4): 517-520|
Montelukast is a potent orally active cysteinyl leukotriene receptor antagonist that significantly improves parameters of asthmatics. A new liquid-liquid extraction based reverse phase liquid chromatography method has been developed and subsequently validated for the determination of montelukast in human plasma. The separation was achieved with C8 column (150×4.6 mm, 5 micron) and a mobile phase comprising of a mixture of 10 mM ammonium acetate buffer (pH 3.0) and acetonitrile in a ratio of 35:65 v/v. Montelukast was extracted from human plasma using a liquid-liquid extraction technique with ter-butylmethylether. The limit of detection and lowest limit of quantification were 5 and 10 ng/ml respectively. This method was found to be linear over the range of 10 to 1000 ng/ml with a recovery of 53 to 62%. Intraday and interday precision (% CV) was <15% and accuracy ranged from 96.23 to 108.39%. Stability studies showed that montelukast in human plasma is stable during the short-term period of sample preparation and analysis. This method can be used with small volume sample during pharmacokinetic studies.
Montelukast ([R-(E)]-1[[[1-[3-[2-(7-chloro-2-quinolinyl) ethyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl) phenyl] propyl]thio] methyl] cyclo propane acetic acid, fig. 1 is a selective and orally active cysteinyl leukotriene (CysLT1) receptor antagonist. It is used for prophylaxis and chronic treatment of asthma [1-3]. Few liquid chromatographic methods with UV detection , fluorescence detection , stereoselective determination of S-enantiomer of montelukast on column switching technique with fluorescence detection ; and 96 well-based extraction methods [7,8] are reported for the assay of montelukast in human plasma. The reported methods are based on either protein precipitation techniques, which are preliminary in nature and nonspecific  or solid phase extraction technique. Emphasis has been laid on the reduction of blood sample volume during analysis and hence less amount of sample withdrawal is required during kinetics-related studies. We report a new liquid-liquid extraction based simple, economic and sensitive HPLC method with fluorescence detection to determine montelukast in human plasma with small plasma sample volume.
Montelukast sodium (Morepen Laboratories Ltd., New Delhi). Blank human plasma (Prathma Blood Bank, Ahmedabad). Quinine sulphate (internal standard), ammonium acetate and sodium bicarbonate (S. D. Fine Chem. Limited, Mumbai). All chromatography solvents were of HPLC grade.
The HPLC system consisted of isocratic pump (Jasco PU980), autosampler (Jasco AS-950-10) and fluorescence detector (Jasco FP-920). Chromatographic separation was achieved by using Kromasil RP-8, 150 × 4.6 mm, 5 micron column (Flexit Jour, Pune). A mixture of 10 mM ammonium acetate buffer (pH 3.0) and acetonitrile (35:65, v/v) was used as mobile phase.
The mixture consisting of 10 mM ammonium acetate buffer (pH 3.0) and acetonitrile (35:65, v/v) was found to be an appropriate mobile phase, allowing adequate separation of drug and the internal standard using a C8 column at a flow rate of 1.0 ml/min. The fluorescence detection was done at excitation and emission wavelengths of 350 and 400 nm respectively. The detector was set on programmed mode, which showed no interference from the endogenous polar impurities (Table 1). Stock solutions of drug and internal standard (100 μg/ml) were prepared in methanol and stored at 4°C. The working standards of 1 μg/ml and 100 ng/ml were prepared and used within 2 w from the date of preparation.
|Linearity||10 - 1000 ng/ml|
|Correlation coefficient (r)||0.99896|
|Limit of detection||5 ng/ml|
|Lowest limit of quantification||10 ng/ml|
|Attenuation||128 (For internal standard) 8 (For montelukast)|
|Internal standard||1.9 min|
|Total run||15.0 min|
Table 1: Summary of method and validation parameters.
To prepare quality control (QC) samples, appropriate volumes from working solutions of montelukast were transferred to 50 ml flask and diluted to the mark with blank human plasma and thoroughly mixed. The concentrations of montelukast were 30, 150 and 800 ng/ml in blank human plasma to represent low, middle and high controls (HQC, MQC and LQC) respectively. The QC samples were stored at -80°C.
Fifty microlitres of internal standard (10 μg/ml of quinine sulphate in methanol) was added to each 200 μl of human plasma samples and vortexed for 10 s. Saturated solution of sodium bicarbonate (50 μl) was added to it, followed by vortexing for 10 s. Ter-butylmethylether (2 ml) was added, followed by vortexing for 2 min and centrifuged at 5000 g for 5 min. Organic layer was transferred to another set of labelled test tubes. Organic layer was evaporated under nitrogen. Residue was dissolved in 150 μl of mobile phase and 100 μl of this sample was injected for analysis.
Calibration curves were prepared by adding known amounts of montelukast (2, 4, 8, 15, 50, 100 and 200 ng) to 200 μl of blank human plasma. An aliquot of 50 μl of the internal standard in methanol (10 μg/ml) was added to each sample. The samples were extracted as described above. The standard curves were constructed by plotting ‘the peak area ratio of montelukast to that of internal standard’ versus ‘their respective concentrations.’ The calibration curves were obtained by least square linear regression analysis. The calibration curves showed linearity over the range of 10-1000 ng/ml for montelukast. The coefficient of correlation was found to be more than 0.99.
For intraday precision and accuracy, six replicates of QC plasma samples of montelukast (6, 30 and 160 ng/200 μl) were extracted as described above and the concentrations were calculated from the standard curve; while for interday precision and accuracy, six replicates of QC plasma samples of montelukast (6, 30 and 160 ng/200 μl) were analysed on three consecutive days, along with the standard calibration curves. Results of intraday, interday precision and accuracy are shown in Table 2.
|Amount added (ng/ml)||Intra day (ng/200 ml)||Inter day (ng/200 ml)||Accuracy* %|
|N||SD (±)||% CV||N||SD (±)||% CV|
*Mean of six replicates
Table 2: Assay precision and accuracy of montelukast
In order to calculate recovery of the extraction procedure, six QC plasma samples of montelukast (800 and 150 ng/ml) were analysed and the peak area ratios of montelukast to that of internal standard were compared with those of unextracted montelukast in mobile phase (Table 1).
For bench top stability, three replicates of montelukast (HQC, MQC and LQC) were analysed at 0 and 24 h at room temperature; while for autosampler stability, three replicates of montelukast (HQC, MQC and LQC) were analysed at 0 and 24 h at room temperature; and for freeze-thaw stability, three replicates of montelukast (HQC, MQC and LQC) were frozen at -20° and analysed after 1, 2, 3 and 4 freeze-thaw cycles. The stability studies showed that montelukast in human plasma are stable during short-term periods of sample preparation and analysis.
A typical HPLC chromatogram of extracted sample of human plasma spiked with 30 ng/ml of montelukast with internal standard and blank human plasma is illustrated in fig. 2. The retention times of internal standard and montelukast were 1.9 min and 12.0 min respectively with total run time of 20 min.
A new liquid-liquid extraction based method has been developed and subsequently validated for the determination of montelukast in human plasma with small plasma sample volume with fluorescence detection. This method has been found to be specific and cost-effective and can be used for quantitative analysis of montelukast during bioavailability/ bioequivalence studies and clinical trials.
Authors are thankful to the Industries Commissionerate, Gujarat State, India, for financial support towards the instrumentation facilities; and Ms. Swati Guttikar and Ms. Aswini Ozha for their guidance.
- Budhavari, S., Eds; In; The Merck Index. 12th Edn., Merck & Co. Inc., Whitehouse Station, NJ, 1999, 6337.
- Prafitt, K., Edn., In; Martindale, The Complete Drug Reference, 33rd Edn., The Pharmaceutical Press, London, 1999, 756.
- Morrow, J.D. and Roberts, L.J., In; Hardman, J.G. and Limbird, L.E., Eds., The Pharmacological Basis of Therapeutics, 10th Edn., McGraw Hill, New York, 2001. 677.
- Radhakrishna, T., Narasaraju, A., Ramakrishna, M and Satyanarayana, A., J. Pharm. Biomed. Anal., 2003, 31, 359.
- Arsarra, I.A., Saudi Pharm. J., 2004, 12, 136.
- Liu, L., Cheng, H., Zhao, J.J. and Roger, J.D., J. Pharm. Biomed. Anal., 1997, 15, 631.
- Kitchen, C.J., Wang, A.Q., Musson, D.G., Yang, A.Y. and Fisher, A.L., J. Pharm. Biomed. Anal., 2003, 31, 647.
- Smith, G.A., Rawls C.M. and Kunku R.L., Pharm. Res., 2004, 21, 1539.
- Hohyan K., Kyu Y.C., Chang H.P., Moon S.J., Jung A.L., Hee J.L. and Kyung R.L. Chromatographia 2004, 60, 93.